Amanda Tivnan
Overview
Explore the profile of Amanda Tivnan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
645
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Salvucci M, Zakaria Z, Carberry S, Tivnan A, Seifert V, Kogel D, et al.
BMC Cancer
. 2019 Nov;
19(1):1092.
PMID: 31718568
Background: The evasion of apoptosis is a hallmark of cancer. Understanding this process holistically and overcoming apoptosis resistance is a goal of many research teams in order to develop better...
2.
Murray J, Valli E, Yu D, Truong A, Gifford A, Eden G, et al.
Eur J Cancer
. 2017 Jul;
83:132-141.
PMID: 28735070
The ATP-binding cassette transporter ABCC4 (multidrug resistance protein 4, MRP4) mRNA level is a strong predictor of poor clinical outcome in neuroblastoma which may relate to its export of endogenous...
3.
Tivnan A, Heilinger T, Ramsey J, OConnor G, Pokorny J, Sarkaria J, et al.
Oncotarget
. 2017 Feb;
8(10):16605-16620.
PMID: 28178667
Aromatase is a critical enzyme in the irreversible conversion of androgens to oestrogens, with inhibition used clinically in hormone-dependent malignancies. We tested the hypothesis that targeted aromatase inhibition in an...
4.
Tivnan A, Heilinger T, Lavelle E, Prehn J
J Neurooncol
. 2016 Oct;
131(1):1-9.
PMID: 27743144
Glioblastoma (GBM) is an aggressive brain tumour, associated with extremely poor prognosis and although there have been therapeutic advances, treatment options remain limited. This review focuses on the use of...
5.
Tivnan A, Zakaria Z, OLeary C, Kogel D, Pokorny J, Sarkaria J, et al.
Front Neurosci
. 2015 Jul;
9:218.
PMID: 26136652
Glioblastoma multiforme (GBM) is a highly aggressive brain cancer with extremely poor prognostic outcome despite intensive treatment. All chemotherapeutic agents currently used have no greater than 30-40% response rate, many...
6.
Cheung L, Flemming C, Watt F, Masada N, Yu D, Huynh T, et al.
Biochem Pharmacol
. 2014 Jun;
91(1):97-108.
PMID: 24973542
Multidrug resistance protein 4 (MRP4/ABCC4), a member of the ATP-binding cassette (ABC) transporter superfamily, is an organic anion transporter capable of effluxing a wide range of physiologically important signalling molecules...
7.
Tivnan A, Zhao J, Johns T, Day B, Stringer B, Boyd A, et al.
Tumour Biol
. 2013 Sep;
35(2):1459-65.
PMID: 24068568
Reduced levels of specific microRNA in cancer are frequently reported and associated with attenuated cancer genes and associated pathways. We previously reported a loss of miR-124a in glioblastoma (GBM) patient...
8.
Tivnan A, McDonald K
Mol Neurobiol
. 2013 Apr;
48(3):757-68.
PMID: 23625340
Glioblastoma (GBM) is a highly aggressive brain cancer with the worst prognosis of any central nervous system disease despite intensive multimodal therapy. Inevitably, glioblastoma is fatal, with recurrence of treatment-resistant...
9.
Tivnan A, Orr W, Gubala V, Nooney R, Williams D, McDonagh C, et al.
PLoS One
. 2012 Jun;
7(5):e38129.
PMID: 22662276
Background: Neuroblastoma is one of the most challenging malignancies of childhood, being associated with the highest death rate in paediatric oncology, underlining the need for novel therapeutic approaches. Typically, patients...
10.
Bray I, Tivnan A, Bryan K, Foley N, Watters K, Tracey L, et al.
Cancer Lett
. 2011 Feb;
303(1):56-64.
PMID: 21310526
Several studies have implicated the dysregulation of microRNAs in neuroblastoma pathogenesis, an often fatal paediatric cancer arising from precursor cells of the sympathetic nervous system. Our group and others have...